VolitionRx Limited (NYSE American: VNRX) announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan, enabling full automation in central laboratories through the IDS i10 automated analyzer platform. The company said the transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows, with more than 1,700 veterinary hospitals in Japan already registered to use the test.
Volition highlighted Japan’s approximately seven million pet dogs and noted the automated platform aligns with the same system used for its human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy. The validation marks a critical step in scaling the veterinary cancer test, which detects nucleosomes associated with cancer in dogs. By automating the process, Volition can process larger volumes of samples more efficiently, which is essential as the test gains adoption among veterinary practices.
The Nu.Q Vet Cancer Test is a simple blood test that helps veterinarians detect cancer in dogs earlier, potentially improving outcomes. The automation through the IDS i10 platform is expected to reduce manual labor and errors, allowing central laboratories to handle increasing demand. This development is particularly important in Japan, where pet ownership is high and veterinary care is advanced. The test’s integration with the same platform used for human diagnostics also suggests potential for shared technology and streamlined operations across Volition’s product lines.
VolitionRx is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. The company develops and commercializes simple, cost-effective blood tests to detect and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. For more information, visit the company’s website at https://volition.com/.
The full press release is available at https://ibn.fm/k076y.
